Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II everolimus plus octreotide LAR in advanced nonfunctional well-differentiated gastrointestinal neuroendocrine tumors
2010-023422-20Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Dec 2010
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and octreotide in gastrointestinal neuroendocrine tumor, sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: 12-month progression-free survival. Started Dec 2010; status: completed.
02
Drugs
everolimusoctreotide
03
Conditions
gastrointestinal neuroendocrine tumor
Beyond the preview
Go deeper on 2010-023422-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023422-20.